Follow us on LinkedIn
In the recent virtual regional event from the UK’s Bioindustry Association (BIA) conversations and debates focused on the topic of advanced therapies in the South West.
eXmoor’s CEO and founder Angela Osborne chaired the main session, which saw her present on eXmoor’s activities over the past year including our record £12m investment from MVM. Angela also spoke on her plans for the future of the company, such as our recruitment drive and plans for a new bigger lab facility.
This was followed by individual presentations from the three event speakers, looking at the exciting developments and success stories from the region in recent months, across the full developmental pathway. From developing very early-stage start-ups through to expanding well-established companies.
Paul Lloyd-Evans (NHSBlood and Transport (NHSBT))
Paul, head of the clinical biotechnology centre, began his talk with the vision for NHSBT:
“To establish NHSBT as the preferred provider of stem cell therapies to the NHS and of innovative cellular & molecular therapies for NHS, academic and commercial organisations seeking to enhance the range of treatments available, aligned with the government strategies to develop infrastructure in this area.”
The presentation then went on to discuss a new clinical biotechnology centre facility that the company is planning. This world class £10.6milion multi-product purpose-built facility aims to create a centre of excellence for cell and gene therapies in Filton, Bristol. Paul spoke on how they hope the centre will double capacity for DNA plasmids to four production lines as well as diversifying their viral vector capabilities and services.
Moin Saleen (Purespring/ University of Bristol)
Moin Saleem is a professor of paediatric renal medicine at the University of Bristol, as well as Founder and CSO of Purespring Therapeutics. His presentation looked at gene therapy for the kidney, from concept to commercial tractability.
Purespring Therapeutics are the world’s first kidney gene therapy company, born out of the University of Bristol after a £45m series A investment from Syncona. Their challenge is to target the kidney, via glomerular podocyte with AAV technology. If successful they will unlock the curative therapy for a number of major kidney conditions.
From their current research Moin and his team have concluded that the journey from concept to commercial reality is feasible. It does though, require input from experts for the different stages, to guide the academics and university team. As well as this, a greater and more flexible understanding of mutual needs of academia and industry is key to develop this life changing treatment.
Carolyn Porter (Cytoseek)
Director and CTO of Cytoseek, Carolyn Porter presented on how her and her team are working to enable the next generation of cell therapies.
Their versatile IP protected AMBP platform addresses current challenges in cell therapies. They have been applying AMBP platform to immuno-oncology field to improve the effectiveness of cell therapies targeting solid tumours.
The current business model is to develop AMBP enhanced cell therapy products and to seek co-development partnerships with cell therapy developers. Cytoseek have most recently raised £3.57M which was led by a new fund in the South West. They now look to raise more funds to be able to expand the AMBP platform to other cell therapies and identify lead candidates prior to a Series A funding round in 2023.
Panel debate and Q&A
Following the presentations, Angela ran a panel discussion, in which the panellists considered why the South West has been at the centre of all of these stories, and what can be done to maintain and build on them in future.
They compared the pull of the region from an employability point of view and how it compared to the natural pull of the conventional triangle of London, Oxford and Cambridge.
The session ended with a virtual networking session, that saw attendees placed on digital tables, to discuss the afternoons presentation and connect with their industry peers.
Overall, the event showed the South West as a booming area of development for the bioindustry and we’re excited to see the results of the new facilities plans and treatment trials that were discussed.
eXmoor, the expert cell and gene therapy (CGT) services company (Bristol, England), has announced an initial investment of £12m ($17m) from specialist healthcare investment firm MVM Partners (“MVM”), to enable eXmoor’s ambitious expansion plans. This will create a new dedicated 50,000 ft2 CGT process development and clinical manufacturing facility in Bristol (UK).
eXmoor has expanded rapidly over the last 5 years, developing a portfolio of clients across the UK and internationally, completing over 400 projects across 15 countries to date.
In 2017, eXmoor added process development laboratories to its consultancy base, with world leading expertise in viral vector process development. Today, eXmoor’s globally recognised team of scientists, consultants and engineers delivers end-to-end CGT biomanufacturing projects, supporting businesses in commercialising research processes and developing fully licensed facilities.
The investment from MVM denotes a key milestone in eXmoor’s international growth strategy. The deal will facilitate expansion plans to create the new, dedicated CGT facility which will be designed in-house by eXmoor’s highly experienced, Capital Projects team led by Director Gavin Sutton. The new facility will increase capacity for process development and add early phase clinical GMP (good manufacturing practice) for cell therapies, gene therapies and viral vectors. The business will also grow and develop its Translation Consultancy and Capital Project teams. The growth plans will see significant job creation with staff headcount projected to increase from 40 to 200, within 5 years.
Based in Boston and London, MVM focusses on investing in high growth healthcare businesses. MVM will bring CGT and associated services experience and strategic insight to the business, with MVM partner Thomas Casdagli joining the eXmoor board of directors and Jack Tanaka joining as board observer.
Thomas and Jack bring a wealth of experience having been part of major healthcare and pharmaceutical businesses at board level in several international healthcare companies. MVM will hold a significant minority stake in eXmoor as part of the deal.
The longer-term impact of the investment and eXmoor’s planned expansion will support CGT process development at a critical time. The UK is a world leader in CGT research; eXmoor will help organisations commercialise this huge research base as well as providing additional manufacturing capacity particularly in the viral vector area, acknowledged as lacking global capacity.
In readiness for the expansion, eXmoor has formed a new senior leadership team and welcomes former CEO of McLaren Applied Technologies, Ian Rhodes, into the business as Director of Consulting and Finance. Ian has extensive experience in leading high growth businesses through their scale-up phases.
Angela Osborne, founder and chief executive officer of eXmoor said: “MVM has a proven track-record working with healthcare and pharmaceutical organisations globally. This deal gives us a strong foundation for our future growth, not just in the UK and Europe but further into other international markets, particularly North America. CGT is such an important area in biomedical research and one that has the ability to treat, prevent and potentially cure diseases that affect people all over the world.
“The Bristol area is a great place to build on our highly skilled and knowledgeable consultancy and process development teams, attracting talent from the excellent local universities in Bristol, Bath and Cardiff.
“We have been fortunate to be able to continue and expand our operations at the University of the West of England in the Future Space innovation centre operated by Oxford Innovation and we would like to thank them for their continued support.”
Thomas Casdagli, partner at MVM, commented: “eXmoor is a pioneer in cell and gene therapy manufacturing and has one of the most experienced teams in all elements of translating CGT innovation into scalable and robust manufacturing processes. With this investment eXmoor now has the broadest and most flexible range of CGT services in the market. eXmoor can support its clients from PD, to GMP and commercial stage manufacturing either in a dedicated facility specified and supported by eXmoor or in a facility run by eXmoor. I am thrilled to support the company at this pivotal time and look forward to working with the wider team in the months to come.”
eXmoor’s advisors to the transaction were Foot Anstey (legal) and PKF Francis Clark (financial).
We are very pleased to announce the following staff promotions at eXmoor Pharma from Scientist 1 to Scientist 2 in the lab team:
- Emilie van der Gronden has taken on increasing responsibility since joining eXmoor’s DSP team in October 2019, including leadership our client intermediate hold studies, some key DSP process development studies, and chairing the Staff Engagement Group.
- Ambra Albertario joined eXmoor in February 2019 as part of the USP team and is continuing to lead one of our client’s material generation series projects successfully, as well as contributing to our C-Prep system development. She is also developing her leadership skills via participation in her BIA cohort.
- Mike Kilcooley has been working in the USP team since September 2019 and has made a strong contribution to our bioreactor campaigns, and as study lead for USP process development involving Ambr systems and 10L bioreactor runs; he is also project managing our electronic lab notebook project implementation.
Congratulations to Emilie, Ambra, and Mike, their promotions are well deserved, and we are excited to see how they progress with their careers at eXmoor. Their technical and leadership skills are second-to-none and it is a pleasure to see them deliver real value for our clients.
These promotions are examples of our strong commitment to support staff growth and invest in training and development, and critical to expanding our operations and advancing our growth plans.
We have chosen to support our local charity Bristol North West Food Bank as our 2021 Charity of the Year with a £10,000 donation.
Every year, eXmoor Pharma selects a charity to support in the Bristol and South West region, and 2021 sees the consultancy giving its largest donation to date, reflecting the growth of eXmoor as a company and the development and expansion of its lab team in Bristol.
eXmoor employees decide the charity for that year, with the Bristol North West Food Bank receiving the most votes from staff, this comes at a time when food donations are needed more than ever.
When asked about the donation, Emma Murray, Bristol North West Food Bank Manager said: “Thank you so very much for the extremely generous donation of £10,000. We are absolutely delighted to receive such an amazing donation from eXmoor.
“We support those in crisis with emergency food and our clients include the elderly, the vulnerable, those suffering domestic abuse, people on low income etc. We are seeing an increase in the need for food by people who have lost their jobs due to Covid-19 and of course we are seeing a rise in those struggling with their mental health due to the Pandemic.”
“eXmoor’s kind donation will be spent in various ways – we will be able to continue to buy in fresh fruit and vegetables which are so important for our clients to have. We also need a container to store non-perishable food in so we always have plenty of food in stock for our clients and we can now hire two storage containers for two years with this money which will make a huge difference to our storage capacity and the money will also be well spent on our other operational costs.”
Angela Osborne, founder and chief executive officer at eXmoor Pharma said: “The work done by the Bristol North West Food Bank in our area is outstanding. We are proud to support them as our Charity of the Year for 2021 and hope that our donation will allow them to continue to help those that need it, during this difficult time.
“Our Charity of the Year project has been a tradition for some years now and is something we value very highly at eXmoor and plan to continue.”
Last year, eXmoor donated to the Julian Trust, a night shelter for the homeless in Bristol, as well as The Ocean Cleanup, an organisation designing and developing clean-up systems to clean-up plastic polluting our oceans and to intercept plastic on its way to the ocean via rivers.
In 2019, its chosen Charity of the Year was Macmillan Cancer Support, a leading cancer charity offering emotional, physical and financial support to people affected by cancer.
Our CEO, Angela Osborne, is to present on the role of Process Engineering in Cell and Gene Therapy (CGT) Manufacturing to an audience from the Institute of Chemical Engineers (IChemE) at a webinar event on 4th February.
Chief executive officer Angela Osborne will host IChemE’s latest free-to-attend webinar following her award of the prestigious industry accolade the Donald Medal last year.
Angela will explore the rapid growth of CGT and how it is now at a global scale, attracting significant VC and PE interest. The session will include examples in both process and facility development where process engineering principles can and have been applied to accelerate the route to market.
IChemE is the leading global professional qualifying body for chemical, biochemical and process engineers which exists to advance the worldwide contribution of chemical engineering for the benefit of society.
Last year, Angela was awarded IChemE’s Donald Medal. Named after a long-serving honorary secretary of IChemE and former Ramsay Professor at University College London, Maxwell Bruce Donald. The accolade is awarded annually by the Biochemical Engineering Special Interest Group (BESIG).
Angela received the award in recognition of her pioneering work in the field of cell and gene therapy manufacturing. She is the first female recipient of the award since its fruition in 1989.
Commenting, Angela said: “I felt very honoured to receive the medal last year and it is humbling to be in the company of previous winners such as Peter Dunnill and Malcolm Lilly, who pioneered biochemical engineering. I am delighted to be presenting the latest innovations and work from the cell and gene therapy manufacturing sector. I hope that attendees will gain an understanding of the importance of process engineering principles in process and facility development within this area of manufacturing.”
The webinar on 4th February is aimed at biochemical engineers with an interest in cell and gene therapy.
To register for the webinar please visit: https://www.icheme.org/membership/communities/special-interest-groups/biochemical-engineering/events/04-02-21-process-engineering-in-cell-and-gene-therapy-manufacturing/
Following the success of the BIA MAC Leadership Programme (LeaP), May saw the kick-off of the LeaP Alumni Association.
The LeaP initiative was established to develop senior leaders of the future in the biopharmaceutical and cell and gene therapy industries. To date, 68 participants from 24 companies have joined the LeaP initiative, with each graduating cohort producing ever more enthusiastic future leaders in the early stages of their careers.
The LeaP Alumni Association aims to expand the benefits of the initiative beyond the initial 2 years of the programme, providing graduates with a growing network of past participants and organising opportunities to meet at BIA networking events. The Alumni Association will also aim to provide support for new LeaP cohorts.
As recent graduates of the programme, Will Milligan (eXmoor pharma) and Chris Sadler (AbbVie) will help to establish the LeaP Alumni Association and provide initial leadership. Christina Baklori (PALL) and Luke Cutmore (Oxford Biomedica) will be the first LeaP Advocates. As Advocates, Christina and Luke will be on hand to support the most recent cohorts through their 2-year journey and give friendly advice and guidance when needed.
The obvious challenge will be to set up a networking association in the age of social distancing! The initial focus of the team will be to support the current cohorts virtually and to promote communication with the current alumni.
Find out more about the LeaP Initiative here: https://www.bioindustry.org/policy/skills-people-and-talent/bia-mac-leap.html
Ambra joined eXmoor in February 2019 as a bioprocess scientist in our cell and gene therapy commercialisation lab in Bristol. Already a key part of the team, we caught up with her to find out a little more about her role within the team, her day-to-day work, and how she’s been settling in.
What does your role entail?
I’m part of the Upstream Development team and my job is predominantly lab-based. I’m responsible for the technical execution of client projects, analysing data, supporting experimental design and providing input on project reports and study protocols.
Our commercialisation lab focuses on developing and optimising manufacturing processes for cell and gene therapies. Within the Upstream team, we work on optimising the cell culture aspect of the manufacturing process, working to make low risk, efficient manufacturing processes that can be transferred into GMP manufacturing facilities.
It’s a very exciting role and no day is ever the same, which is something I love!
How have you found being part of the eXmoor team?
I’ve settled in really well to the team and I’m very happy to be part of it. My colleagues are all hugely enthusiastic and competent, and everyone has been very friendly and helpful since I joined. It’s a great environment to work in.
Can you tell us a bit about your academic and professional background?
I have a bachelor’s degree in biotechnology and a master’s in medical biotechnology, both of which I achieved in Italy. I moved to Bristol to pursue a PhD in cardiovascular research at the University of Bristol, following which I worked as a technician and then a research associate, in tissue engineering for cardiac surgery.
How did you find joining eXmoor straight from academia?
It was certainly very different compared to academia. The main difference at eXmoor is that we are directly supporting client projects, as opposed to working for yourself or for a publication as you would at a university. This adds an additional layer of responsibility to the work that we do. There’s a great deal more planning required in advance and the work we propose has to be carried out carefully, often to fixed deadlines.
Of course, this can be stressful, but I am really enjoying it because eXmoor is a relatively small organisation, with a lot of expertise in the field, and I feel very supported.
You joined at an exciting time for the company. What do you think is on the horizon for advanced therapies?
It’s a very promising field which is set to be the future for many areas of medicine, especially in treating cancer and genetic diseases.
There are challenges that those working in the industry have to overcome, particularly relating to manufacturing, but that’s what eXmoor has set out to do!
What do you enjoy doing when you’re not in the lab?
I’m a big fan of outdoor activities; walking, sailing, motorcycling and other sports such as tennis, yoga and skiing. Obviously, I do less sailing and skiing now I live in Bristol! But I try and go when I’m back in Italy. I also like to cook and take care of my plants.
What is your proudest achievement?
A few months ago I had my first author paper published in the Journal of the American College of Cardiology, a very high-impact and widely read publication in the industry. This was definitely a very proud moment!
For 2020 eXmoor have chosen two charities to support. This reflects both the growth of eXmoor as a company and the development and expansion of our lab team in Bristol. For 2020, eXmoor are proud to support Julian Trust Night Shelter and Ocean Cleanup.
eXmoor has donated £3000 to Julian Trust, a night shelter for homeless in Bristol. Julian Trust runs throughout the year for 5 nights each week offering evening meals to whoever comes (about 50 to 70 per night) and overnight accommodation & related services for up to 18 homeless people who would otherwise be sleeping on the streets.
Richard Drake, Julian Trust:
“As a charity run entirely by volunteers, we have no staff costs so our costs are primarily utilities, building maintenance and cleaning.
Donations received will go directly towards the costs of running our shelter which run at about £1500 per week, so £3,000 will keep us going for 2 weeks – thank you for that donation”
eXmoor has also donated £2000 to Ocean Cleanup, an organisation designing and developing cleanup systems to clean up plastic already polluting our oceans and to intercept plastic on its way to the ocean via rivers.
A significant percentage of the plastic that enters the oceans from rivers and other sources during a transfer that can take many years, drifts into large systems of circulating ocean currents. This plastic will slowly break down into microplastics and become increasingly easier to mistake for food by sea life. The Ocean Cleanup’s ultimate goal is a 90% reduction of floating ocean plastic by the year 2040.
Last year, our Charity of the Year was Macmillan Cancer Support, a leading cancer charity offering emotional, physical and financial support to people affected by cancer
EIs vs BIs – Enzyme Indicators vs Biological Indicators
Obtaining accurate qualification results as quickly as possible is the minimum expectation and this is certainly the case when it comes to decontamination performance validation.
As such, the use of Biological Indicators (BIs) for decontamination qualification are a significant bottleneck and Enzyme Indicators (EIs) are an exciting potential solution for the biopharmaceutical industries.
The Limitations of BIs
The conventional method for Vapor Phase Hydrogen Peroxide (VPHP) cycle development is to use resistant BIs to challenge the decontamination of enclosed spaces, which range from positive pressure isolators to whole rooms.
With this approach, the aim of the biodecontamination cycle is to demonstrate a 6-log reduction of the BI -despite this acceptance criterion usually being applied to terminal sterilisation processes, rather than for decontamination (i.e. disinfection).
To put this into context, the Environmental Protection Agency (EPA) classification of cleaning agents describes VPHP as a disinfectant treatment, for which demonstration of 4-log reduction of bacterial spores would be an acceptable result. However, BIs can only provide a kill (6-log)/no kill result.
This is a time-consuming process, since a seven-day incubation period is required for definitive confirmation of a successful cycle. This in turn means that cycle development is costly and requires a huge amount of manual processing.
Recent developments in thermally stable adenylate kinase (tAK) technology Enzymatic Indicators (EIs) are presenting an exciting alternative to the use of BIs, an alternative which is both rapid and capable of providing a much more precise indication of the level of disinfection.
In comparison with processes utilising BIs, cycles using EIs can be analysed rapidly, assuring confirmation of decontamination performance.
Any active enzyme remaining on strips following exposure are analysed on an indicator utilising a luciferin reaction which provides an immediate residual light output that is directly comparable to the remaining activity on the test strip.
The test strips can be manufactured to a high degree of consistency, with none of the quality issues that BIs may be vulnerable to.
Public Health England and Protak Ltd have carried out detailed enumeration studies using BIs and tAK EIs to develop inactivation profiles of tAK against log kill. In this way, a rapid and reliable assay for a range of desired log kills, including those suitable to demonstrate decontamination, is available to industry.
With the instant results provided by EIs using tAK before release, decontamination cycles can be quickly modified in the event of failure, meaning that cycle development is accelerated and the time to successful manufacture reduced. Additionally, the technology means that microbiologists can obtain a full product decontamination and manufacturing history, lowering the risk of batch failures.
EIs could be the future of decontamination performance validation for reasons ranging from accuracy, to time to production and cost.
However, the future of EI solutions such as those using tAK (or other developing technologies) requires further comparative work against previously validated systems. One entry possibility is the validation of EIs alongside BIs during periodic revalidations of existing systems.
For 2019 we have chosen Macmillan Cancer Support as our Charity of the Year.
Macmillan believes no one should face cancer alone and the charity does a range of fantastic things to support those living with the disease, from raising money to fund nurses and therapists to providing support centres with information resources such as booklets and leaflets.
But it doesn’t stop there! Macmillan also works hard to run campaigns to improve cancer care and fight discrimination, and to provide more information and support centres offering free and confidential advice.
We recently donated £4,000 to the charity to show our support for the amazing and life-changing help and care that Macmillan provides. Donations help the charity be there every step of the way for those living with cancer as well as for their friends, families, carers and communities.
Last year, our Charity of the Year was Alzheimer’s Research UK, the leading dementia research charity dedicated to making life-changing breakthroughs in diagnosis, prevention, treatment and cure.
As a team, eXmoor is always looking for fun ways to raise money for its chosen charities. Head to https://www.macmillan.org.uk/get-involved/all-ways-to-help.html to find out more and let us know if you have any great ideas!
Cell and gene therapy manufacturing consultancy eXmoor Pharma is working with Orchard Therapeutics (ORTX: NASDAQ) on the concept design of a new gene therapy manufacturing facility in Fremont, California, US.
Orchard, a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, recently announced it has signed a long-term lease agreement to build-out a new facility in California.
eXmoor will be working with Orchard and its local partners to develop the concept design of the new gene therapy manufacturing facility which is expected to create more than 100 new jobs in the San Francisco Bay Area to support the company’s extensive gene therapy pipeline and enhance its capacity to develop and deliver lentiviral vector and gene-corrected hematopoietic stem cells for a wide range of diseases on a global scale.
The concept design will comprise process design as well as architectural plans for the lentiviral vector and cryopreserved cell therapy manufacturing suites and their associated support facilities. eXmoor will deliver a package suitable for Orchard to have initial discussions with regulatory agencies and to allow local partners to progress to finalisation of the architectural and engineering designs.
“The expansion of our California operation to include a manufacturing facility is a critical step in advancing Orchard’s capabilities to supply products for our ex vivo gene therapy programs,” said Stewart Craig, Ph.D., chief manufacturing officer of Orchard.
“We are very pleased to be able to collaborate with such an expert group as eXmoor and our local partners to efficiently advance our plans to support the potential launch of our gene therapy clinical product candidates.”
eXmoor Pharma managing director Angela Osborne commented: “We’re thrilled to be working on the concept design for Orchard’s new facility and to support the company’s mission of transforming patient’s lives through gene therapy.
“We are expert in delivering innovative end-to-end GMP biomanufacturing projects and, with our knowledge, experience and structured process, eXmoor will provide Orchard with the tailored design solution to suit the specific requirements of their new gene therapy manufacturing facility in California.”
Angela founded eXmoor Pharma in 2004 and has since grown it into a globally recognised leader in its field that has completed more than 300 projects across 12 countries including the design of 27 cell and gene therapy facilities.
Notes to editors:
eXmoor Pharma is a cell and gene therapy and biopharmaceutical manufacturing consultancy which was founded in 2004 and has since grown into a globally recognised leader in its field that has completed more than 300 projects across 12 countries.
The company works closely with clients to help them with commercialising a research process, developing fully licensed facilities and providing QP services. eXmoor has won repeat business from nearly two thirds of all its clients since its launch.
eXmoor’s offices and process development laboratories are in Bristol, UK.
Orchard Therapeutics is a fully integrated commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies.
Orchard’s portfolio of autologous ex vivo gene therapies includes Strimvelis, the first autologous ex vivo gene therapy approved by the European Medicines Agency for adenosine deaminase severe combined immunodeficiency (ADA-SCID). Additional programs for neurometabolic disorders, primary immune deficiencies and hemoglobinopathies include three advanced registrational studies for metachromatic leukodystrophy (MLD), ADA-SCID and Wiskott-Aldrich syndrome (WAS), clinical programs for X-linked chronic granulomatous disease (X-CGD) and transfusion dependent beta-thalassemia (TDBT), as well as an extensive preclinical pipeline.
Orchard currently has offices in the U.K. and the U.S., including London, San Francisco and Boston.
For further information contact:
Tel: 0117 925 1358
Angela founded the biopharmaceutical and cell therapy manufacturing consultancy eXmoor Pharma in 2004 and has since grown it into a globally recognised leader in its field that has completed more than 300 projects across 12 countries.
In September 2010 she co-founded the Advanced Therapy Medicinal Products (ATMP) Manufacturing Community, or amc, to build critical mass and facilitate the sharing of expertise in ATMP manufacturing. The amc now boasts 170 fee paying members.
Angela is a member of the BioIndustry Association (BIA)’s Cell Therapy Industry Group and Manufacturing Groups’ advisory committees, .
She has now been named alongside 49 other ‘outstanding’ female healthcare business leaders in the 2018 BioBeat list which aims to emphasise the role of women leading and innovating to ensure new technologies and treatments continue to improve UK research, health and society.
Angela said: “It is a real honour to be included on this BioBeat list alongside so many other inspiring women working in UK healthcare businesses.
“There is amazing work being done by women across the board developing new products and processes and pushing the boundaries of bioscience in ways that will hopefully benefit everyone in years to come.
“My inclusion on this list is really thanks to the hard work and dedication of all our talented team at eXmoor who between them have more than 300 years’ combined experience in gene and cell therapy and biopharmaceuticals.”
eXmoor Pharma works closely with clients to help them with commercialising a research process, developing fully licensed facilities and providing QP services. The company has won repeat business from nearly two thirds of all its clients since its launch.
Miranda Weston-Smith, BioBeat founder, said: “Congratulations to the outstanding women leaders who are recognised as the 50 Movers and Shakers in BioBusiness 2018.
“They are changing what is possible for the benefit of humanity and helping to build a more inclusive, responsive healthcare ecosystem – whether that’s by developing revolutionary products, shaping bioscience through investment, accelerating the innovation pipeline, transforming patient access to healthcare or supporting innovation from concept to market.”
Jane Osbourn, vice-president research and development at MedImmune, which supported the report, said: “On behalf of the numerous partners and supporters of the 50 Movers and Shakers in BioBusiness 2018 report, we are delighted to celebrate the achievements of this group of talented women. We hope shining a spotlight on these female leaders will support them to forge stronger networks and realise new opportunities to improve patient health.”
An innovation platform for healthcare entrepreneurs which brings together scientific and business expertise, BioBeat has celebrated 50 Movers and Shakers in BioBusiness every year since 2014.
BioBeat connects entrepreneurs with leaders in biotech, by working to respond to challenges and open opportunities through the inspirational experience of women leaders. Miranda Weston-Smith founded BioBeat to bring fresh energy and insights into biotech for a healthier world.
BioBeat is grateful to long-standing partners the Cambridge Judge Entrepreneurship Centre and Innovation Forum.
Each autumn, BioBeat releases the 50 Movers & Shakers in BioBusiness report, which identifies 50 women in the UK who are shaking up biotech translation. The annual autumn summit also brings together pioneers in biotech to nurture innovation and new partnerships.
Find out more at http://www.mws-consulting.co.uk/biobeat/
At eXmoor, we wanted to share our top 10 ‘must have’ requirements when sourcing a new site for a Generic ATMP Manufacturing Facility.
1. Area and Capacity
The prospective site area must be a suitable size to include the manufacturing site and warehouse, laboratories, offices, meeting rooms, reception and any other rooms or buildings that may be required. It’s important to consider all planned projects as these will give a good indication of the capacity required at the new site.
In accordance with regulatory guidance, between 6-8m of space will be needed above the cleanrooms to include a walk-on ceiling which will allow these areas to be serviced from the outside. Space will also need to be made available for suitable heating, ventilation and air conditioning (HVAC) through the manufacturing and office areas. If the prospective building has sufficient height, the HVAC units could be located above the cleanrooms.
3. Vertical Distribution
Isolated lifts must be included for the movement and distribution of supply materials, waste and the final product. The number of lifts will depend on the layout of the prospective building. An additional large goods lift installed to allow for the vertical transportation of motors and spares to the plantroom (if required).As per point 2, a walk-on ceiling must be included above the cleanrooms to allow for servicing. Finally, you should allow for door heights of 2.7m to enable movement of large pieces of equipment throughout the facility.
When choosing a site, always consider whether there is a suitable flow and segregation of personnel, materials and waste. It’s also important to take into account the number of lifts and external docking stations.
5. Co-occupancy and Access
Ideally the site and facility chosen should always be single occupancy and should never share incoming or outgoing routes with other occupants of the building. It should not be possible to mix materials, personnel or waste routes with other occupants of the building, and no one should not be able to obtain unauthorised access to the facility (via lifts or stairs).
The following raw utility services will need to be supplied as standard to the facility:
- Mains pressure water
- Surface and foul drainage
- Gas (optional)
- Electrical power
The following utilities should also be considered (if relevant to the facility):
- Water for injection
- Deionised water
- Pure steam
- Plant steam
- Process chilled water
- Clean in place
- HVAC units to service cleanrooms – depending on concept design
Ensure there is sufficient space on-site for the following items:
- Chiller compound
- Waste compound
- Gases and LN2 area
- Generator compound of sufficient size
The following items should also be considered in regards to the site proximity:
- Not near to standing water or falls in an area with a high flood risk
- Not near to heavily polluted industrial air exhausts
- Not near to an adjacent large scale construction site
- Ideally the manufacturing area would be >1m above the ground floor
The location of the manufacturing facility is important to consider. It should be in close proximity to public transport links, amenities and in a safe working area. As first impressions are always important, the buildings and larger site should be smart and well maintained, portraying a professional and high quality image to others.
In the manufacturing area there will be large items of equipment that will impose a significant live loading on the floor, and there are therefore minimum loading requirements:
- In the office / general areas, the minimum requirement for live floor loadings is 2.5kN/m2 above ground floor and 3.0kN/m2 at ground floor
- In the manufacturing and plant areas, live loads need to be in accordance with the minimum standard (BS EN 1991-1-1:2002) of 7.5kN/m2, ideally 10.0kN/m2 to allow for 1000kg pallet (8.2kN/m2)
10. Support Areas
In the warehouse areas, storage should be of a sufficient capacity to allow various categories of materials and products to be stored in an orderly manner. Enough space should also be allocated to avoid any mix-ups or cross-contamination during the quality checking process and testing. Quality control laboratories should also be kept separate from the production areas. Rest and refreshment rooms should be kept separate from the production, storage and quality control areas. Toilets and washrooms should not directly link with production, storage and quality control areas.
Typical walk on ceiling, allowing for external maintenance and HVAC.
Typical corridor, design and constructed
In March this year the MHRA published its guidance on GxP Data Integrity.
We have welcomed the guidance at eXmoor. It provides specific information which is invaluable to companies around the practical steps which should be taken to ensure best practice at every stage of handling, managing and storing data.
In the past companies relied upon a perceived best practice along with general references to GAMP5 and 21CFR11 compliance, which has led to inconsistencies in the way data was managed. We believe this document will help companies understand the expectations around assurance of data integrity and that we will now see a more uniform approach and a move towards better managed data integrity practices.
The time is also right for this guidance. Technology and data storage products are now more advanced and becoming more common place within the industry; for example, the use of cloud-based technology for data storage has its benefits for the industry, but also holds risks which should be controlled.
We know from the manufacturers we work with that the guidance has helped them to review their data lifecycle and has resulted in updated processes in how they deal with data.
A major focus of the guidance has meant more emphasis on risk assessments of facilities and processes specifically around the data produced and how it is used. This is enabling a more holistic view of data management. The recommendation is to invest time in performing comprehensive Data Integrity Risk Assessments (DIRA) allowing companies to categorise their data management systems and to apply an appropriate level of control.
As part of this and to ensure compliance we are advising on how best to invest in the preparatory phase of any new facility or project and analysis of all the data which will be produced once operational.
Understanding the data lifecycle from start to finish, i.e. from when data is generated to when it is disposed of, is paramount. This then facilitates the validation of those systems used during that data lifecycle. The MHRA describes the data lifecycle as the ‘generation and recording through processing (including analysis, transformation and migration), use, date retention, archive/retrieval and destruction.’
Examples of where risk to data integrity can occur, which may impact on established working practices, are as follows:
- Non-synchronised clocks: important when setting up systems that need to ensure the time and date on data is accurate and consistent ensuring concurrent recording of actions.
- Access rights: unique user identification is vital to prevent unauthorised amendment of data. The guidance emphasises that having a single user access that does not uniquely identify the operator should not be used.
Companies with legacy systems may not have this feature. This will require them to assess the need for having other support systems in place (third party software or paper based) which provide a record of unique user identification.
- Provision of a suitable work environment: As part of our facility design work we consider whether sufficient space has been allocated for an operator to be able to record data. Companies should always consider space for laying out of a batch record and SOP as part of the process.
Further features of the MHRA Data Integrity guidance:
- Scribes: the use of scribes should be contemporaneous with the task being performed and the records should identify the person performing the task. The person performing the task should verify the actions taken at a suitable time after task completion.
- Raw data: the guidance states that where the system permits dynamic storage then this cannot be replaced by paper systems.
- True copies: these are considered to be a copy of the original record which has been verified as having the same information as the original.
- Electronic signatures: Companies should ensure signature processes are appropriately validated to ensure that suitability and control is maintained.
- Computerised systems validation: The MHRA has expressed the need for companies to look at all the systems they use within their processing and understand the computerised elements and the risks they pose and then apply a suitable level of control.
It is not acceptable to take a suppliers’ statement of compliance as the sole guarantee as to the acceptability of a computerised system – there needs to be some level of qualification performed by the company purchasing the system; the level required should be determined through risk assessment in the same manner as any processing equipment. As an example, an analytical instrument will be supplied with 21CFR 11 compliant software, but how the company intend to use the software needs to be assessed. This will need to take into account user set up and access rights, baseline configurations of the software, the programming of methods, data analysis, data reporting and data storage.
The importance of data management has never been more pronounced, and we believe this new guidance will provide both manufacturers and suppliers a clearer understanding as to the expectations from the competent authorities.
The hope is that companies will be able to manage their data more appropriately rather than taking the historical approach of ‘keep everything’ and that it will galvanise industry to use the data it generates to assist them in ensuring the quality of the products produced.
For more information and to access the full guidance document click here: https://www.gov.uk/government/publications/guidance-on-gxp-data-integrity
For more information on how eXmoor help our clients with this topic click here: https://www.exmoorpharma.com
The R&D version of our novel CPrep equipment is now ready for trials. This equipment gently and automatically thaws and washes a cell therapy and then fills a syringe ready for administration. It will help to extend the shelf life of valuable products, remove uncertainty in the final processing step and increase patient safety.
Commercially available CPrep has resulted from a joint project with Amercare Ltd, and a grant from the UK’s innovation agency, Innovate UK. R&D versions may be trialled in our labs in Bristol and are manufactured by Amercare Ltd. The supply chain for the GMP version will be finalised to suit the specific needs of individual cell therapies.